secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001683168-23-009006
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals holds virtual investor update; no specific results disclosed
--------------------------------------------------------------------------------

- Company held a virtual update meeting on Dec 21, 2023 with CEO John Climcao and CMO Dr. Sandra Silberman.
- Meeting link provided in filing but no financial or clinical data included in the 8-K.
- Filing under Regulation FD; no material new information furnished in the report.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823009006/0001683168-23-009006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823009006/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-009006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer